Cirrhosis Clinical Trials

Find Cirrhosis Clinical Trials Near You

ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition, physical activity, socio-demographic conditions, tobacco, alcohol, pollutants) on the occurrence of the main type of liver cancer (called HCC). Indeed, in the vast majority of cases, HCC develops within cirrhosis, and the factors that precipitate the progression of cirrhotic patients to HCC remain largely unknown.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Presence of metabolic and/or alcoholic steatotic liver disease, as defined by the new nomenclature (MASLD, ALD, or mixed MetALD)

• Liver biopsy performed (less than 2 months ago) or planned as part of treatment for diagnosis of cirrhosis (Control group without HCC) or diagnosis of HCC on cirrhosis (Case group)

• Patient affiliated to or benefiting from a social security scheme

• Patient having signed an informed consent to participate in the study (bio-collection)

Locations
Other Locations
France
Angers University Hospital
RECRUITING
Angers
Centre Eugène Marquis (Oncology center)
NOT_YET_RECRUITING
Rennes
Rennes University Hospital, Hepatogastroenteroly Department
NOT_YET_RECRUITING
Rennes
Tours University Hospital, HepatoGastroenterology Department
NOT_YET_RECRUITING
Tours
Contact Information
Primary
Jérôme BOURSIER, Professor
JeBoursier@chu-angers.fr
+33 (0)2 41 35 64 28
Backup
Matthieu LE LAY, Master
matthieu.lelay@chu-angers.fr
+33 (0)2 41 35 58 91
Time Frame
Start Date: 2025-12-17
Estimated Completion Date: 2029-03
Participants
Target number of participants: 300
Treatments
Other: Control group
Group of patients with MASLD and/or ALD at cirrhosis stage, without HCC
Other: Case group
Group of patients with MASLD and/or ALD at cirrhosis stage and complicated by HCC
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Angers

This content was sourced from clinicaltrials.gov